

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT**

Docket Number:
10162/91

Application Number
Not Yet Assigned

Filing Date
Herewith

Examiner
Not Yet Assigned

Art Unit
Not Yet Assigned

Invention Title
CONTRAST AGENTS

Inventor(s)
Jo KLAVERNESS et al.

Address to:
Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Patent Owner hereby bring the attached references to the attention of the Examiner. The attached references were collected from a review of files transferred to the law firm of Kenyon & Kenyon as well as from interferences 103,880, 103,881 and 104,154 and litigation. These references are listed on the attached modified PTO form 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Copies of each patent, publication or other information listed on the modified PTO Form 1449 are not enclosed because they were previously cited in the parent application Serial No. 10/640,504 of which the present case is a continuation.
3. The applicant also wishes to draw the attention of the Examiner to the following co-pending applications and patents:

U.S.S.N.	Filing Date	
08/478,733	6/7/95	US Pat. 6,106,806 (08/22/2000)
09/197,918	11/23/98	(Abandoned)

U.S.S.N.	Filing Date	
09/255,112	2/22/99	(Abandoned)

08/734,167	10/21/96	(Abandoned)
09/231,351	1/13/99	
09/089,128	6/2/98	(Abandoned)
08/936,164	9/23/97	(Abandoned)
09/227,410	1/8/99	

and the following pending applications and patents which are related to application U.S. S.N. 07/761,311:

U.S.S.N.	Filing Date
90/005,000	5/15/98
90/004,656	6/3/97
90/004,657	6/3/97
08/896,821	7/18/97
90/004,972	4/21/98
08/466,104	6/6/95
08/745,256	11/8/96
08/896,821	7/18/97
08/710,849	9/23/96
08/646,910	5/8/96
08/900,986	7/25/97

U.S. Patents	Grant Date
4,858,208	8/15/89
6,156,292	12/05/00

4. It is further noted by the Applicant that U.S. Serial Nos. 08/467,289 and 08/513,831(US Pat. 5,960,183 09/28/99) are U.S. equivalents to U.S. counterpart WO 94/21302;

U.S. Serial No. 08/469,522 (Abandoned)is the U.S. counterpart to WO 96/06518;

AU 89/30351 is equivalent to WO 89/06978; and

AU 89/40651, AU 641,363 and DE 89/00548 are equivalent to WO 90/01952.

5. English abstracts and/or translations accompanied all foreign language documents in the Information Disclosure Statement filed on March 29, 2000 in the parent application.

6. The applicant also wishes to draw the attention of the Examiner to the Complaint and a First Amended Complaint filed against the Assignee by Alliance Pharmaceutical Corporation, Civil Action No. 98CV 171 2E LAB (S.D. Cal.) filed 9/21/98 and 11/6/98 respectively, which accompanied the Information Disclosure Statement filed on March 29, 2000 in the parent application.

Dated: *April 7, 2004*

By: *Elizabeth M. Wieckowski*
Elizabeth M. Wieckowski, Reg. No. 42,226

KENYON & KENYON
One Broadway
New York, N.Y. 10004
(212) 425-7200 (telephone)
(212) 425-5288 (facsimile)
CUSTOMER NO. 26646

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket No.
10162/91

Serial No.
Not Yet Known

APPLICANT
Jo Klaveness et al.

Filing Date
Herewith

Group
Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE
	1	1,644,446	10/4/27	Rapp			
	2	2,659,690	11/17/53	Slaybaugh			
	3	3,291,843	12/13/66	Fritz et al.			
	4	3,539,682	11/10/70	Eriksson et al			
	5	3,557,294	1/19/71	Dear et al.			
	6	3,615,972	10/26/71	Morehouse et al.			
	7	3,650,831	3/21/72	Jungermann et al.			
	8	3,663,687	5/16/72	Evans			
	9	3,720,761	3/13/73	Hunter			
	10	3,832,457	8/27/74	Sugimoto et al.			
	11	3,900,420	8/19/75	Sebba			
	12	3,932,805	1/13/76	Abe et al.			
	13	3,968,203	7/6/76	Spitzer et al.			
	14	4,027,007	5/31/77	Messina			
	15	4,101,435	7/18/78	Hasegawa et al.			
	16	4,107,288	8/15/78	Oppenheim et al.			
	17	4,229,360	10/21/80	Schneider et al.			
	18	4,235,871	11/25/80	Papahadjopoulos et al.			
	19	4,244,179	1/13/81	Kainov et al.			
	20	4,247,406	1/27/81	Widder et al.			
	21	4,265,251	5/5/81	Tickner			
	22	4,276,885	7/7/81	Tickner et al.			
	23	4,316,391	2/23/82	Tickner			
	24	4,329,332	5/11/82	Couvreux et al.			
	25	4,331,654	5/25/82	Morris			

	26	4,335,094	7/15/82	Mosbach			
	27	4,357,259	11/2/82	Senyei et al.			
	28	4,371,516	2/1/83	Gregory et al			
	29	4,427,649	1/24/84	Dingle et al.			
	30	4,442,843	4/17/84	Rasor et al.			
	31	4,452,773	6/5/84	Molday			
	32	4,466,442	8/21/84	Hilmann et al.			
	33	4,501,726	2/26/85	Schröder et al.			
	34	4,544,545	10/1/85	Ryan et al.			
	35	4,572,203	2/25/86	Feinstein			
	36	4,615,879	10/7/86	Runge et al.			
	37	4,657,756	4/14/87	Rasor et al.			
	38	4,663,161	5/5/87	Mannino et al.			
	39	4,675,173	6/ 23/87	Widder			
	40	4,681,119	7/21/87	Rasor et al.			
	41	4,684,479	8/4/87	D'Arrigo			
	42	4,687,748	8/18/87	Schröder			
	43	4,713,249	12/15/87	Schröder			
	44	4,718,433	1/12/88	Feinstein			
	45	4,731,239	3/15/88	Gordon			
	46	4,767,611	8/30/88	Gordon			
	47	4,770,183	9/13/88	Groman et al.			
	48	4,774,958	10/4/88	Feinstein			
	49	4,778,657	10/18/88	Spohr			
	50	4,827,945	5/9/89	Groman et al.			
	51	4,832,941	5/23/89	Berwing et al.			
	52	4,844,882	7/4/89	Widder et al.			
	53	4,858,208	8/15/89	Swapp			
	54	4,863,715	9/5/89	Jacobsen et al.			
	55	4,871,716	10/3/89	Longo			
	56	4,900,540	2/13/90	Ryan et al.			
	57	4,904,479	2/27/90	Illum			
	58	4,918,065	4/17/90	Stindl et al.			

	59	4,957,656	9/18/90	Cerny et al.			
	60	4,985,233	1/15/91	Klaveness et al.			
	61	4,986,980	1/22/91	Jacobsen			
	62	5,008,109	4/16/91	Tin			
	63	5,069,936	12/3/91	Yen			
	64	5,077,057	12/31/97	Szoka , Jr.			
	65	5,088,499	2/18/92	Unger			
	66	5,107,842	4/28/92	Levene et al.			
	67	5,141,738	8/25/92	Rasor et al.			
	68	5,147,631	9/15/92	Glajch et al.			
	69	5,149,319	9/22/92	Unger			
	70	5,196,348	3/23/93	Schweighardt et al.			
	71	5,205,290	4/27/93	Unger			
	72	5,228,446	7/20/93	Unger et al.			
	73	5,271,928	12/21/93	Schneider et al.			
	74	5,271,961	12/21/93	Mathiowitz et al.			
	75	5,281,408	1/25/94	Unger			
	76	5,310,540	5/10/94	Giddey et al.			
	77	5,334,381	8/2/94	Unger			
	78	5,348,016	9/20/94	Unger,et al.			
	79	5,352,435	10/4/94	Unger			
	80	5,362,478	11/8/94	Desai et al.			
	81	5,380,519	1/10/95	Schneider et al.			
	82	5,393,524	2/28/95	Quay			
	83	5,409,688	4/25/95	Quay			
	84	5,413,774	5/9/95	Schneider et al.			
	85	5,425,366	6/20/95	Reinhardt et al.			
	86	5,445,813	8/29/95	Schneider et al.			
	87	5,456,900	10/10/95	Unger			
	88	5,456,901	10/10/95	Unger			
	89	5,469,854	11/28/95	Unger et al.			
	90	5,501,863	3/26/96	Rössling et al.			
	91	5,508,021	4/16/96	Grinstaff et al.			

	92	5,512,268	4/30/96	Grinstaff et al.			
	93	5,527,521	6/18/96	Unger			
	94	5,529,766	6/25/96	Klaveness et al.			
	95	5,531,980	7/2/96	Schneider et al.			
	96	5,536,489	7/16/96	Lohrmann et al.			
	97	5,536,490	7/16/96	Klaveness et al.			
	98	5,542,935	8/6/96	Unger et al.			
	99	5,547,656	8/20/96	Unger			
	100	5,552,133	9/3/96	Lambert et al.			
	101	5,556,610	9/17/96	Yan et al.			
	102	5,558,094	9/24/96	Quay			
	103	5,558,853	9/24/96	Quay			
	104	5,558,854	9/24/96	Quay			
	105	5,558,855	9/24/96	Quay			
	106	5,558,856	9/24/96	Klaveness et al.			
	107	5,558,857	9/24/96	Klaveness et al.			
	108	5,559,266	9/24/96	Klaveness et al.			
	109	5,562,893	10/8/96	Lohrmann			
	110	5,567,413	10/22/96	Klaveness et al.			
	111	5,567,415	10/22/96	Porter			
	112	5,573,751	11/12/96	Quay			
	113	5,578,291	11/26/96	Porter			
	114	5,578,292	11/26/96	Schneider et al.			
	115	5,585,112	12/17/96	Unger et al.			
	116	5,597,549	1/28/97	Schneider et al.			
	117	5,599,523	2/4/97	Beller et al.			
	118	5,605,673	2/25/97	Schutt et al.			
	119	5,607,661	3/4/97	Berg et al.			
	120	5,614,169	3/25/97	Klaveness et al.			
	121	5,618,514	4/8/97	Schröder et al.			
	122	5,626,833	5/6/97	Schutt et al.			
	123	5,637,289	6/10/97	Klaveness et al.			
	124	5,637,564	6/10/97	Pavia et al.			

	125	5,639,433	6/17/97	Yuan et al.			
	126	5,639,442	6/17/97	Unger et al.			
	127	5,639,443	6/17/97	Schutt et al.			
	128	5,643,553	7/1/97	Schneider et al.			
	129	5,648,062	7/15/97	Klaveness et al.			
	130	5,653,959	8/5/97	Tournier et al.			
	131	5,658,551	8/19/97	Schneider et al.			
	132	5,666,526	9/9/97	Reiter et al.			
	133	5,670,135	9/23/97	Schröder			
	134	5,674,468	10/7/97	Klaveness et al.			
	135	5,676,925	10/14/97	Klaveness et al.			
	136	5,686,060	11/11/97	Schneider et al.			
	137	5,688,490	11/18/97	Tournier et al.			
	138	5,693,321	12/2/97	Klaveness et al.			
	139	5,695,741	12/9/97	Schutt et al.			
	140	5,701,899	12/30/97	Porter			
	141	5,705,187	1/6/98	Unger			
	142	5,711,933	1/27/98	Bichon et al.			
	143	5,714,528	2/3/98	Unger et al.			
	144	5,714,529	2/3/98	Unger et al.			
	145	5,716,597	2/10/98	Lohrmann et al.			
	146	5,718,884	2/17/98	Klaveness et al.			
	147	5,720,938	2/24/98	Schutt et al.			
	148	5,720,939	2/24/98	Schröder			
	149	5,730,954	3/24/98	Albayrak et al.			
	150	5,730,955	3/24/98	Lohrmann			
	151	5,733,572	3/31/98	Unger et al.			
	152	5,772,984	6/30/98	Berg et al.			
	153	5,817,291	10/6/98	Schröder			
	154	5,827,502	10/27/98	Klaveness et al.			
	155	5,863,520	1/26/99	Bichon et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUBCLASS	TRANS- LATION YES NO
	156	30351/89	8/25/89	Australia ¹			
	157	31860/93	7/29/93	Australia ²			
	158	25503/92	4/27/93	Australia ³			
	159	86330/82	1/27/83	Australia ⁴			
	160	A1 2,036,107	8/10/91	Canada			
	161	0 032 622 A1	7/29/81	EPO			
	162	0 052 575 A2	5/26/82	EPO			
	163	0 063 002 A2	10/2/82	EPO			
	164	0 071 564 A	2/9/83	EPO			
	165	0 077 752 A2	4/27/83	EPO			
	166	0 122 624 A2	10/24/84	EPO			
	167	0 123 235 A2	10/31/84	EPO			
	168	0 131 540 A2	1/16/85	EPO			
	169	0 136 812	4/10/85	EPO			
	170	0 212 568 A2	3/4/87	EPO			
	171	0 212 588 A1	3/4/87	EPO			
	172	0 224 934 A2	6/10/87	EPO			
	173	0 231 091 A1	8/5/87	EPO			
	174	0 274 961 A1	7/20/88	EPO			
	175	0 324 938 A1	7/26/89	EPO			
	176	0 327 490 A1	8/9/89	EPO			
	177	0 357 163 A1	3/7/90	EPO			
	178	0 359 246 A2	3/21/90	EPO			
	179	0 365 467 A2	4/25/90	EPO			
	180	0 398 935 B1	11/28/90	EPO			
	181	0 441 468 A2	8/14/91	EPO			
	182	0 458 745 A1	11/27/91	EPO			
	183	0 494 615 A1	7/15/92	EPO			
	184	0 554 213 A1	8/4/93	EPO			
	185	FR 2429616	1/25/80	France			

	186	FR 2496460	6/25/82	France			
	187	JP B2 2842453	1/6/99	Japan			
	188	JP-A-58-79930	5/13/83	Japan			
	189	JP-A-59-205329	11/20/84	Japan			
	190	DE 2336546 C2	1/31/74	Germany			
	191	DE 2744493 A1	4/13/78	Germany			
	192	DE 3341001 A1	5/23/85	Germany			
	193	DE 3401052 A	7/26/84	Germany			
	194	DE 3529195 A1	2/26/87	Germany			
	195	DE 3637926 C1	11/26/87	Germany			
	196	DE 3803972 A1	8/10/89	Germany			
	197	DE 3834705 A1	4/12/90	Germany			
	198	DE 4219723 A1	12/16/93	Germany			
	199	1,044,680	10/5/66	Great Britain			
	200	1,174,366	12/17/69	Great Britain			
	201	1,339,537	12/5/73	Great Britain			
	202	GB 1 388 796 A	3/26/75	Great Britain			
	203	GB 1 518 121	7/19/78	Great Britain			
	204	GB 1 518 813 A	7/26/78	Great Britain			
	205	GB 1 526 522	9/27/78	Great Britain			
	206	GB 2 042 887 A	10/1/80	Great Britain			
	207	GB 2 134 869 A	8/22/84	Great Britain			
	208	GB 2 135 647 A	9/5/84	Great Britain			
	209	GB 2 137 612 A	10/10/84	Great Britain			
	210	ZA 9100961	1/27/91	South Africa ⁵			
	211	SE A 6904024-4	12/23/74	Sweden			
	212	SE 372 421 B	12/23/74	Sweden ⁶			
	213	SE 79 02009-5 B	1/3/84	Sweden ⁷			
	214	SE 74 07461-8 B	10/19/81	Sweden ⁸			
	215	SE74 07462-6 B	10/19/81	Sweden ⁹			

216	SE 76 07673-6 A.	11/1/82	Sweden ¹⁰			
217	CH 641682 A5	3/15/84	Switzerland			
218	WO 90/02808	3/22/90	PCT			
219	WO 89/00988	2/9/89	PCT			
220	WO 85/04330	10/10/85	PCT			
221	WO 83/03426	10/13/83	PCT			
222	WO 83/03920	11/10/83	PCT			
223	WO 84/02643	7/ 19/84	PCT			
224	WO 84/00294	2/24/84	PCT			
225	WO 78/00005	12/7/78	PCT			
226	WO 83/01738	5/26/83	PCT			
227	WO 82/01006	4/1/82	PCT			
228	WO 82/00099	1/21/82	PCT			
229	WO 84/00294	2/2/84	PCT			
230	WO 92/05806	4/16/92	PCT			
231	WO 91/15244	10/17/91	PCT			
232	WO 92/19272	11/12/92	PCT			
233	WO 92/02560	2/20/92	PCT			
234	WO 95/01187	1/12/95	PCT			
235	WO 92/04392	3/19/92	PCT			
236	WO 93/07905	4/29/93	PCT			
237	WO 90/01952	3/8/90	PCT			
238	WO 91/12823	9/5/91	PCT			
239	WO 93/00930	1/21/93	PCT			
240	WO 94/09625	5/11/94	PCT			
241	WO 92/17212	10/15/92	PCT			
242	WO 93/02712	2/18/93	PCT			
243	WO 94/06477	3/31/94	PCT			
244	WO 88/09165	12/1/88	PCT			
245	WO 85/04326	10/10/85	PCT			
246	WO 94/21302	9/29/94	PCT			
247	WO 94/28780	12/22/94	PCT			
248	WO 96/06518	2/29/96	PCT			
249	WO 93/05819	4/1/93	PCT			
250	WO 92/17213	10/15/92	PCT			

251	WO 92/17514	10/15/92	PCT			
252	WO 91/09629	7/11/91	PCT			
253	WO 92/21382	12/10/92	PCT			
254	WO 89/05160	6/15/89	PCT			
255	WO 80/02365	11/13/80	PCT			
256	WO 94/16739	8/4/94	PCT			
257	WO 94/21301	9/29/94	PCT			
258	WO 89/06978	8/10/89	PCT			
259	WO 84/02838	8/2/84	PCT			
260	WO 84/02909	8/2/84	PCT			
261	WO 92/15284	9/17/92	PCT			
262	WO 88/07365	10/6/88	PCT			
263	WO 94/09829	5/11/94	PCT			
264	WO 95/05854	3/2/95	PCT			
265	WO 93/17718	9/16/93	PCT			
266	WO 92/11873	7/23/92	PCT			
267	WO 85/02772	7/4/85	PCT			

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

268	Abe et al., "Development procedure of magnetic focusing method for NMR medical application" Radiation Medicine 2(1):1-23 (1984).
269	Armstrong et al., "Left ventricular echocardiographic contrast via transpulmonary passage of Albunex", Circulation, 78S:565 (1988).
270	Barnhart, et al., "Characteristics of Albunex", Invest. Radiol. 25:S162-164 (1990).
271	Bäumert, H.G. and Fasold, H. "Cross linking techniques", Methods in Enzymology, 172S:584-609, Academic Press, Inc. (1989).
272	Becker, E.D., <u>High resolution NMR , theory and chemical applications, 2nd Edition</u> , Sidney Fleiscler et al., eds., pages 48-51 and 97, Academic Press, New York (1980).
273	Benita, et al., "Characterization of drug-loaded poly (d, l - lactide) microspheres", J. Pharm. Sci. 73(12):1721-1724 (1984).
274	<u>Biochemistry</u> , 2 nd Edition, Stryer, eds. pp 208-209, Freeman, San Francisco (1981).
275	<u>Blakiston's Gould Medical Dictionary</u> , 4 th Edition, "lecithin", pp 749, McGraw-Hill, New York (1979).
276	Bleeker, H.J. and Shung, K.K., "Ultrasonic characterization of Albunex®, a new contrast agent", J. Acoust. Soc. Am. 87(4):1792-1797 (1990).
277	Bleeker, et al., "On the application of ultrasonic contrast agents for blood flowmetry and assessment of cardiac perfusion", J. Ultrasound Med. 9(8);461-471 (1990).
278	Bommer, et al., "Contrast echocardiography: pulmonary transmission and myocardial perfusion imaging using surfactant stabilized microbubbles", Abstract of the 54 th Scientific Sessions, Circulation 64:203, (1981).
279	Bommer, et al., "The safety of contrast echocardiography; Report of the Committee on Contrast Echocardiography for the American Society of Echocardiography" J. Am. Coll. Cardiol. 3(1):6-13 (1984).

280	Cheronis, N. and Spitzmüller, K., "Studies in ammonolysis. I. The ammonolysis of halogen fatty acids and preparation of α -amino acids", J. Organic Chem. 6:349-375 (1941).
281	Christiansen, et al., "Physical and biochemical characterization of Albunex™, a new ultrasound contrast agent consisting of air-filled albumin microspheres suspended in a solution of human albumin", Biotechnol. Appl. Biochem. 19(3):307-320 (1994).
282	<u>Concise Encyclopedia of Biochemistry</u> , pp 348-349, Walter de Gruyter, Berlin (1983).
283	<u>Condensed Chemical Dictionary, Sixth Edition</u> , "phospholipid", Arthur Rose & Elizabeth Rose, eds., pp 662, 888, Reinhold Publishing Co., New York (1961).
284	<u>Condensed Chemical Dictionary, Ninth Edition</u> , Gessner G. Hawley, ed., pp 391, Van Nostrand Reinhold Publishing Co., New York, 1977.
285	Cox et al., "Structure of an iron-dextran complex", J. Pharm. Pharmacology, 24:513-517 (1972).
286	Crommelin, D.J. "Influence of lipid composition and ionic strength on the physical stability of liposomes", J. Pharm. Sci. 73(11):1559-1563 (1984).
287	Crommelin D.J. and Van Bommel, E.M.G., "Freezeing and freeze drying of liposomes" in: <u>Liposomes as Drug Carriers</u> , K.H. Schmidt, ed., pp 89-93, Georg Thieme Verlag, New York (1986).
288	de Jong, et al., "Principles and recent developments in ultrasound contrast agents", Ultrasonics 29:324-330 (1991).
289	de Jong, et al., "Properties of ultrasound contrast agents", Fourth Annual International Symposium on Contrast Agents in Diagnostic Ultrasound", pp 1-9, May 19, 1998.
290	Davis, et al., "Echogenicity caused by stable microbubbles in a protein lipid emulsion", J. Clin. Ultrasound 9(5):249-252 (1981).
291	Davis S.S. and Illum, L., <i>Colloidal delivery systems- opportunities and challenges, in Site specific drug delivery</i> , E. Tomlinson and S.S. Davis, eds., pages 93-110, J. Wiley (1986).
292	Dawkins, J. and Guest, M., "Molecular weight calibration in steric exclusion chromatography of diblock copolymers of polystyrene and poly(ethylene oxide)", J. Liquid Chromatography 7(9): 1739-1751 (1984).
293	Desir et al., "Myocardial contrast echocardiography with Albunex™: Preliminary observations in an experimental model of reactive hyperemia with varying severity of coronary stenosis", Circulation, 78S:566 (1988).
294	Dick et al., "Reproducible myocardial perfusion with intravenous contrast echocardiography", Circulation, 78S:565 (1988).
295	Dittrich, "Cardiac imaging using optison", Fourth Annual International Symposium on Contrast Agents in Diagnostic Ultrasound", pp 10-11, May 19, 1998.
296	<u>Dorland's Illustrated Medical Dictionary, 26th Edition</u> , "lecithin", pp 721, Saunders, Philadelphia (1981).
297	Douglas et al., <i>Nanoparticles in drug delivery in</i> , Critical reviews in therapeutic drug carrier systems, Stephen D. Bruck, ed., 3:233-261, CRC Press, Inc., Boca Raton (1987).
298	Dupont, "Freon: Technical Bulletin", Dupont Technical Bulletin, pp. 1-8 (1964).
299	Dupont, "Freon Fluorocarbons: properties and applications", Dupont Technical Bulletin, pp. 1-10 (1987).
300	Edwards, P.L. and Jarzynski, J., "Scattering of focused ultrasound by spherical microparticles", J. Acoust. Soc. Am. 74(3):1006-1012 (1983).
301	Epstein, P.S. and Plesset, M.S., "On the stability of gas bubbles in liquid-gas solutions", J. Chem. Phys. 18(11):1505-1509 (1950).
302	Feinstein, "New developments in ultrasonic contrast techniques: transpulmonary passage of contrast agents and diagnostic implications", Echography 6(1):27-33 (1989).

303	Feinstein et al., "Two-dimensional contrast echocardiography. I. In vitro development and quantitative analysis of echo contrast agents", JACC 3(1):14-20 (1984).
304	Feinstein, "Myocardial perfusion imaging: contrast echocardiography today and tomorrow", J. Am. Coll. Cardiol. 8:251-253 (1986).
305	Feinstein et al., "Myocardial contrast echocardiography: examination of intracoronary injections, microbubble diameters, and video-intensity decay", Am. J. Physiol. Imaging 1(1):12-18, (1986).
306	Feinstein et al., "Albunex ®: A new intravascular ultrasound contrast agent; preliminary safety and efficacy results", Circulation, 78S:565 (1988).
307	Feinstein et al., "Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results", J. Am. Coll. Cardiol. 16:316 (1990).
308	Fessi et al., "Nanocapsule formation by interfacial polymer deposition following solvent displacement", Int. J. Pharm. 55(1):R1-R4 (1989).
309	Flory, P.J., "Networks" in: Encyclopedia of Polymer Science and Engineering, Volume 10, pp 95-112, John Wiley & Sons, New York (1987).
310	Fobbe et al., "Color-coded duplex sonography and ultrasound contrast media- demonstration of peripheral renal perfusion defects in an animal experiment", Röfo Fortschr. Geb. Röntgenstr. Neuen Bildgebenden Verfahren 154(3):242-245 (1991).
311	Folda et al., "Polyreactions in Oriented Systems, 29; Formation of oriented polypeptides and polyamides in monolayers and liposomes", Makromol. Chem., Rapid Commun. 3(3):167-174 (1982).
312	Fossheim et al., "Low molecular weight lanthanide contrast agents: in vitro studies of mechanisms of action", JMRI 7:251-257 (1997).
313	Ganguly et al., "Structure of hollow polystyrene microspheres: an SEM study", J. Micro encapsulation 6(2):193-198 (1989).
314	Gardner et al., "A survey of intraocular gas use in North America", Arch. Ophthalmology, 106:1188-1189 (1988).
315	Garrahy et al., "Assessment of abnormal systolic intraventricular flow patterns by doppler imaging in patients with left ventricular dyssynergy" Circ. 82:95 (1990).
316	Gehr et al., "Magnetic particles in the liver: a probe for intracellular movement", Nature 302:336 (1983).
317	Geny et al., "The safety of sonicated human albumin (albunex) for repeated echocardiographic studies in experimental animals", Circ. 82:95 (1990).
318	Goldberg, B.B., "Ultrasonic cholangiography. Gray-scale B-scan evaluation of the common bile duct", Radiol. 118(2):401-404 (1976).
319	Gramiak et al., "Echocardiography of the aortic root", Invest. Radiol. 3:356 (1968).
320	Grieco et al., "Sesquiterpene lactones: total synthesis of (±)-vernolepin and (±)-vernomenin" J. Am. Chem. Soc. 99:5773-5780 (1977).
321	Grinstaff, M. W. and Suslick, K. S., "Air-filled proteinaceous microbubbles: synthesis of an echo-contrast agent", P.N.A.S. 88(17):7708-7710 (1991).
322	Handbook of Pharmaceutical Excipients, "methylcellulose", pp 181-183, American Pharmaceutical Association, Washington, D.C. (1986).
323	Heidenreich et al., "Contrast echo measurement of myocardial perfusion: standardization", Circulation 78S:566 (1988).
324	Heidenreich et al., "Contrast echo: in vitro flow calculation", Circulation, 80S:370 (1989).
325	Heidenreich et al., "In vivo calculation of blood flow with contrast ultrasonography", Circulation 80S:566 (1989).
326	Hellebust, et al., "Biochemical characterization of air-filled albumin microspheres", Biotechnol. Appl. Biochem. 18:227-237 (1993).

327	Helzel, M.V., "Early experience with the use of 'contrast media' for use in ultrasound examination of the upper abdomen", <i>Fortschr. Röntgenstr.</i> 140(3):337-340 (1984).
328	Henry-Michelland et al., "Lyophilization and rehydration of liposomes", <i>Colloids and Surfaces</i> 14:269-276 (1985).
329	Hirt, R. and Berchtold, R., "Zur synthese der phosphatide. Eine neue synthese der kephaline" (Synthesis of phosphatides, a new synthesis of cephalin), <i>Helv. Chim. Acta</i> 40:1928-1932 (1957).
330	Hnatowich et al., "Investigations of a new, highly negative liposome with improved biodistribution for imaging", <i>J. Nucl. Med.</i> 21(7):662-669 (1980).
331	Hosokawa, T. et al., "Palladium (II)-catalyzed acetalization of terminal olefins bearing electron-withdrawing substituents with optically active diols" <i>J. Organic Chem. Soc.</i> 52:1758-1764 (1987).
332	Huang et al., "Coupling of antibodies with liposomes", <u>Liposome Technology Volume III Targeted drug deliver and biological interaction</u> , Chapter 4, pp51-62, CRC Press, Inc., Boca Raton, 1984.
333	Hub et al., "Polymerization of lipid and lysolipid like diacetylenes in monolayers and liposomes", <i>J. Macromol. Sci.-Chem.</i> A15(5):701-715 (1981).
334	Jacobs, "Intraocular gas measurement using A-scan ultrasound", <i>Current Eye Research</i> , 5(8):575-578 (1986).
335	Juliano, R. and Stamp, D., "Interactions of drugs with lipid membranes: characteristics of liposomes containing polar or nonpolar antitumor drugs", <i>Biochimica et Biophysica Acta</i> 586(1):137-145 (1979).
336	Juliano et al., "Interactions of polymerized phospholipid vesicles with cells: uptake, processing and toxicity in macrophages", <i>Biochim. Biophys. Acta</i> 812(1):42-48 (1985).
337	Juliano et al., "Photo polymerized phospholipid vesicles: stability and retention of hydrophilic and hydrophobic marker substances", <i>Biochimica et Biophysica Acta</i> 770(2):109-114 (1984).
338	Kabalnov et al. "Solubility of fluorocarbons in water as a key parameter determining fluorocarbon emulsion stability", <i>J. Fluorine Chem.</i> 50(3):271-284 (1990).
339	Kaul et al., "The unreliability of myocardial contrast two-dimensional echocardiography in assessing the transmural distribution of blood flow", <i>J. Am. Coll. Cardiol.</i> 15:195 (1990).
340	Keller et al., "Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: an experimental evaluation", <i>Am. Heart J.</i> 114(3):570-575 (1985).
341	Keller et al., "Automated production and analysis of echo contrast agents", <i>J. Ultrasound Med.</i> 5(9):493-498 (1986).
342	Keller et al., "Quantitative intraoperative myocardial contrast echocardiography: implications for preventing perioperative infarction", <i>Circulation</i> , 78S:567 (1988).
343	Keller et al., "The behavior of sonicated albumin microbubbles within the microcirculation: a basis for their use during myocardial contrast echocardiography", <i>Circulation Res.</i> 65(2):458-467 (1989).
344	Keller et al., "Albunex: a safe and effective commercially produced agent for myocardial contrast echocardiography", <i>J. Am. Soc. Echo.</i> 2:48 (1989).
345	Kirn, "Microbubbles show promise for enhancing ultrasound signal, image, other applications", <i>JAMA</i> 261(11): 1542 (1989).
346	Kondo, A., <i>Applications and studies of microcapsules</i> , in <i>Microcapsule processing and technology</i> , page 18, J. Wade Van Valkenburg, ed., Marcel Dekker, New York (1979).
347	Krause et al., "Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs", <i>Int. J. Pharm.</i> 27:145-155 (1985).
348	Kurtz, A.B. and Hilbert, P. "Ultrasound case of the day. Cystic neuroblastoma with metastatic disease of the liver", <i>Radiographics</i> 9(2):361-364 (1989).
349	Lauterbur, "Image formation by induced local interactions: examples employing nuclear magnetic resonance", <i>Nature</i> 242:190-191 (1973).

350	Lehrb. d. pharm. Tech., 3., "Lezithine", pp 367, Verlag Chemie, New York (1979).
351	Leserman et al., <i>Covalent coupling of monoclonal antibodies and protein A to liposomes: specific interaction with cells in vitro and in vivo</i> , in Liposome Technology Volume III Targeted drug delivery and biological interaction, Chapter 2, pp29-40, CRC Press, Inc., Boca Raton, 1984.
352	Levene et al., "Characterization of Albunex®", J. Acoust. Soc. Am. Suppl 1, 87:S69-70 (1990).
353	Lincoff et al., "Perfluoro-n-butane: a gas for maximum duration retinal tamponade", Arch Ophthalmol. 101:460-462 (1983).
354	Lincoff et al., "The perfluorocarbon gases in the treatment of retinal detachment", Ophthalmology 90(5): 546-551 (1983).
355	Lincoff et al. "Intravitreal Disappearance Rates of Four Perfluorocarbon Gases," Arch Ophthalmol 102:928-929 (1984).
356	Lincoff et al., "Intravitreal longevity of three perfluorocarbon gases", Arch. Ophthalmology, 98:1610-1611, (1980).
357	Lincoff et al., "Intravitreal expansion of perfluorocarbon bubbles", Arch. Ophthalmology, 98:1646 (1980).
358	Loughery et al., "Study of the circulation by myocardial contrast echocardiography" Echocardiography 7:279-292 (1990).
359	Lunblad, R.L. and Noyes, C.M. , <i>The chemical cross-linking of peptide chains</i> , in Chemical Reagents for Protein Modification , Vol II, page 123 CRC Press Inc , Boca Raton, 1984.
360	Luney et al., "Relationship between lipid accumulation by ¹ H NMR spectroscopy and acylcarnitine/triglyceride content in myocardial infarction" Circ. Supp. III 82:261 (1990).
361	Makino et al., "Preparation and in vitro degradation properties of polyactide microcapsules", Chem. Pharm. Bull. 33(3):1195-1202 (1985).
362	Mansfield, P. and Morris, P.G. , <i>NMR imaging in biomedicine</i> , in Advances in Magnetic Resonance, Supp. 2 pages v, vi, 234 Academic Press, Inc., New York (1982).
363	Mattrey et al., "Perfluorooctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material", Radiology 145:759-762 (1982).
364	Medeiros, et al., "Radioaerosol 99mTc-DTPA characterization produced by some nebulizers", Brazilian J. of Med. Biol. Res. 27(7):1561-1573 (1994).
365	Merck Index, 9 th Edition., M. Windholz, ed., "lecithin", pp 711-712, Merck & Co., Rahway (1976).
366	Methoden Der Organischen Chemie: Makromolekulare Stoffe, (H. Bartl and J. Falbe, eds.; Georg Thieme Verlag) 1987.
367	Miller, et al., "Physicochemical approaches to the mode of action of general anesthetics", Anesthesiology, 36:339-351 (1972).
368	Moad, G. and Solomon, D. <i>azo-bis-isobutyronitrile</i> , in Comprehensive Polymer Science 3:99, Geoffrey C. Eastmond et al. eds., Pergamon Press, Oxford (1989).
369	Möhwald, H., "Phospholipid and phospholipid-protein monolayers at the air/water interface", Annu. Rev. Phys. Chem. 41:441-476 (1990).
370	Morrison, R.T. and Boyd, R.N., <i>Organic Chemistry</i> , 3 rd Edition, pp 454, Allyn and Bacon, Inc., Boston (1978).
371	Myrset, et al., "Structure and organization of albumin molecules forming the shell of air-filled microspheres: evidence for a monolayer of albumin molecules of multiple orientations stabilizing the enclosed air", Biotechnol. Appl. Biochem. 24(2):145-153 (1996).
372	Nakamura et al., "Magneto medicine : biological aspects of ferromagnetic fine particles" , J. Applied Physics 42(4):1320-1324 (1971).
373	Newbower, "Magnetic fluids in the blood", IEEE Transactions on magnetics, 9(3):447-450 (1973).

374	Nomura, et al., "US contrast enhancement of hepatic tumor with helium gas microbubbles; a preliminary report", Jpn J. Med. Ultrasonics 18(5):28-35 (1991).
375	Ohara, et al., "Preparation of ethylcellulose-polystyrene composite microcapsules of 2-phase structure and permeability of the microcapsule membranes toward phenobarbital", J. Membrane Sci., 23 (1):1-9 (1985).
376	Ohgushi et al., "Dextran-magnetite: a new relaxation reagent and its application to T_2 measurements in gel systems" J. Magnetic Resonance 29:599-601 (1978).
377	Ohta, et al., "Effect of the contrast agent and the agitation method on the size, number and stability of microbubbles: a basic experiment for the myocardial contrast study", Jpn. J. Med. Ultrason. 18(4):318-326 (1991).
378	Okamoto H., et al., "Retention of perfluorochemicals in circulating blood and organs of animals after intravenous injection of their emulsions." Chem. Pharm. Bull. (Tokyo) 23:1452-1457 (1975).
379	Ophir, J. and Parker, K., "Contrast agents in diagnostic ultrasound", Ultrasound in Med. & Biol. 15(4):319-333 (1989).
380	Ostro, "Liposomes", Scientific American 256(1):102-111 (1987).
381	Özer, et al., "Influence of freezing and freeze-drying on the stability of liposomes dispersed in aqueous media", Acta Pharm. Tech. 34(3):129-139 (1988).
382	Paleos, C., "Polymerization in organized systems", Chem. Soc. Reviews 14(1):45-67 (1985).
383	Paltauf, F. and Hermetter, A., <i>Phospholipids- natural, semisynthetic and synthetic, in Phospholipids- Biochemical, Pharmaceutical, and Analytical Considerations</i> , Israel Hanin & Giancarlo Pepeu, eds., pp1-4, Plenum Press, New York, 1990.
384	Peters, et al., "The nonexpansile, equilibrated concentration of perfluoropropane gas in the eye", Am. J. Ophthalmology 100:831-839 (1985).
385	Peeters, et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates", J. Immunological Methods 120:133-143 (1989).
386	Perry, M.P. "A survey of ferromagnetic liquid applications", in Thermomechanics of magnetic fluids: theory and applications, B. Berkovsky, ed., pages 219-230, Hemisphere Publishing Co., Washington (1977).
387	Pfeiffer, et al., "Glycerolipids. III. Stereospecific syntheses of D- and L-1,2-diglycerides via glycerol carbonates", J. Organic Chem. 35(1):221-224 (1970).
388	Pietersen, "A new warning system for fires of electrical origin", <i>CERN-Service d'information scientifique</i> RD/221, 5000, pp. 1-5 (1977).
389	Ping, Q., et al., "Aggregation and gelation of a polymerisable diacryloyl derivative of poloxamer 407", Int. J. Pharmaceutics 61:79-84 (1990).
390	Technical Insights, Inc., Polymerized Liposomes, Technical Insights, Inc., Fort Lee, (1988).
391	Price, et al., "Polymerization and copolymerization using high intensity ultrasound", British Polymer Journal 23:63-66 (1990).
392	<u>Properties of liquids and solutions</u> , J.N. Murrel and E. A. Boucher, eds., pp 276, John Wiley & Sons, New York (1982).
393	Puisieux, P.F. and Benita, S., "Liposomes: technological problems posed by their use as vectors or drug substances; encapsulation, sterilization, preservation", Bull. Soc. Pharm. Bordeaux, 123:111-126 (1984).
394	Regen et al., "Polymerized phosphatidylcholine vesicles. Synthesis and characterization" J. Am. Chem. Soc. 104(3) 791-795 (1982).
395	Reisner, S.A. et al., "Efficacy and safety of myocardial perfusion imaging using intracoronary sonicated albumin in humans", Circulation, 78S:565 (1988).
396	Reisner, S.A. et al., "Evaluation of coronary blood flow reserve by quantitative myocardial contrast echo", Circulation, 80S:370 (1989).

397	<u>Remington's Pharmaceutical Sciences</u> , Fifteenth Edition, John E. Hoover, Editor, pp 736, Mack Publishing Co., Easton (1975).
398	<u>Remington's Pharmaceutical Sciences</u> , Fifteenth Edition, John E. Hoover, Editor, pp 1242-1244, Mack Publishing Co., Easton (1975).
399	Richardson et al., "Possible tumor localization of Tc-99m-labeled liposomes: effects of lipid composition, charge, and liposome size", J. Nucl. Med. 19(9):1049-1054 (1978).
400	<u>Rompps Chemie Lexikon</u> , 8 th Edition, Vol 2, Cm-G, "Gefriertrocknung", Franckh'sche Verlagshandlung, pp1422-1423, W. Keller & Co., Stuttgart (1981).
401	<u>Rompps Chemie Lexikon</u> , 8 th Edition, Vol 3, H-L, Franckh'sche Verlagshandlung, pp 2380, W. Keller & Co., Stuttgart (1983).
402	<u>Rompps Chemie Lexikon</u> , 8 th Edition, Vol 4, M-Pk, Franckh'sche Verlagshandlung, pp 3159-3160, W. Keller & Co., Stuttgart (1985).
403	<u>Rompps Chemie Lexikon</u> , 8 th Edition, Vol 4, M-Pk, "Lecithine", Franckh'sche Verlagshandlung pp 2474, W. Keller & Co., Stuttgart (1989-1992).
404	Rongved et al., "Starch microsphere as carriers for X-ray imaging contrast agents: Synthesis and stability of new amino-acid linker derivatives", Carbohydrate Res. 297(4):325-331 (1997).
405	Rongved et al., "Cross-linked, degradable starch microspheres as carriers of paramagnetic contrast agents for magnetic resonance imaging: Synthesis, degradation, and relaxation properties", Carbohydrate Res. 214(2):325-330 (1991).
406	Rongved et al., "Polysaccharides as carriers for magnetic resonance imaging contrast agents: synthesis and stability of a new amino acid linker derivative", Carbohydrate Res. 287:77-89 (1996).
407	Runge et al., "Work in progress: potential oral and intravenous paramagnetic NMR contrast agents" Radiology 147(3):789-791 (1983).
408	Runge et al., "Particulate oral NMR contrast agents", Int. J. Nucl. Med. Bull. 12(1):37-42 (1985).
409	Schlieff et al., "Successful opacification of the left heart chambers on echocardiographic examination after intravenous injection of a new sacchride based contrast agent" Echocardiography 7:61-64 (1990).
410	Schlieff et al., "Enhanced color doppler echocardiography of the left heart after intravenous injection of a new saccharide based agent in humans" Circ. Supp. III 82:28 (1990).
411	Schlieff, R., "Ultrasound contrast agents", Curr. Opin. Radiol. 3(2):198-207 (1991).
412	Schlieff et al., "Blood-pool enhancement with SH U 508 A. Results of phase II clinical trials.", Invest. Radiol., 26, suppl.1: S188-9, S198-200 (1991).
413	Schneider et al., "BR1: a new ultrasonographic contrast agent based on sulfur hexafluoride-filled microbubbles", Invest. Radiol. 30(8):451-457 (1995).
414	Schulz, R.C., <u>Acrolein Polymers</u> , in Concise Encyclopedia of Polymer Science and Engineering, pp 12-13 (1990).
415	Schulz, R.C., "Acrolein Polymers" in: <u>Encyclopedia of Polymer Science and Engineering</u> , Volume 1, Mark et al. eds., pp. 164-169, John Wiley & Sons, New York (1985).
416	Segar et al., "Hemodynamic factors affecting left ventricular echocardiographic contrast with albunex", Clin. Res. 37:294A (1989).
417	Shapiro et al., "Intravenous contrast echocardiography with use of sonicated albumin in humans: systolic disappearance of left ventricular contrast after transpulmonary transmission", J. Am. Coll. Cardiol. 16:1603-1607 (1990).
418	Silverman et al., "Safety and efficacy of ultrasound Albunex® injections in humans", Circulation 80S:369 (1989).
419	Singh, A and Schnur, J.M. " Polymerized diacetylenic phosphatidyl choline vesicles: synthesis and characterization", Polymer Preprints 26(2):184-185 (1985).
420	Smith et al., "Left heart opacification with peripheral venous injection of a new saccharide echo contrast agent in dogs" JACC 13(7):1622-1628 (1989).

421	Spilde et al., "Evaluation of an experimental low-attenuation gastrointestinal contrast agent for the CT diagnosis of intestinal ischemia"; manuscript presented at the 83 rd Scientific Assembly and 1997 Annual Meeting of the RSNA.
422	Stark et al., "Nuclear magnetic resonance imaging of experimentally induced liver disease", <i>Radiology</i> 148(3): 743-751 (1983).
423	Swanson, D., <i>Enhancement agents for ultrasound: fundamentals</i> , in <i>Pharmaceuticals in Medical Imaging</i> , radiopaque contrast media radiopharmaceuticals enhancement agents for magnetic resonance imaging and ultrasound, Chapter 22, D.P Swanson, H.M. Chiton and J.H. Thrall, eds., pp 682-687, MacMillan Publishing, New York, 1990.
424	Szoka, F. and Papahadjopoulos, D., "Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation", <i>PNAS</i> 75(9):4194-4198 (1978).
425	Tanaka et al., "Noninvasive measurement of biological information by nuclear magnetic resonance: measurement of relaxation time of a particular target by magnetic focusing method" <i>Proc. of the IEEE</i> 66(11):1582-1583 (1978).
426	Tanaka et al., "" Sogo Rinsho 30:2609-2614 (1981).
427	Tomlinson, "Microsphere delivery systems for drug targeting and controlled release", <i>Int. J. Pharm. Tech. and Prod. Mfr.</i> 43(3):49-57 (1983).
428	Tyrrell et al. "New aspects of liposomes", <i>Biochim et Biophys. Acta</i> 457:259-302 (1976).
429	Ulmus et al., "Molecular organization in the liquid-crystalline phases of lecithin-sodium cholate-water systems studied by nuclear magnetic resonance", <i>Biochem.</i> 21:1553-1560 (1982).
430	Ultrasound: Its applications in medicine and biology, Francis J. Fry, ed., Chapter 1, paragraph 4.9, Elsevier, New York (1978).
431	Ultrasound: Its applications in medicine and biology, Francis J. Fry, ed., Chapter 2, paragraph 1.52, Elsevier, New York (1978).
432	Uno et al. "A new method of preparing monocoated water-loaded microcapsules using an interfacial polymer deposition process", <i>J. Microencapsulation</i> 1(1):3-8 (1984).
433	Violante et al., "Particle stabilized bubbles for enhanced organ ultrasound imaging", <i>Invest. Radiol.</i> 26, Suppl 1:S194-S200 (1991).
434	Vygantas et al. "Octafluorocyclobutane and Other Gases for Vitreous Replacement" <i>Arch Ophthalmol</i> 90: 235-236 (1973).
435	Wehrli et al., <i>Parameters determining the appearance of NMR images</i> , in <i>Modern Neuroradiology</i> Vol. 2, <i>Advanced Imaging Techniques</i> , Thomas H. Newton and D. Gordon Potts, eds., page 97, Clavadel Press, San Anselmo (1983).
436	Wheatley et al., "Contrast agents for diagnostic ultrasound: development and evaluation", <i>Biomaterials</i> 11 (9):713-717 (1990).
437	Woodle, M. and Papahadjopoulos, D., "Liposome preparation and size characterization", <i>Methods in Enzymology</i> 171:193-217 (1989).
438	Ziskin, et al. "Contrast Agents for Diagnostic Ultrasound" <i>Invest. Radiol.</i> , Vol. 7, pp. 500-505 (1972).
439	Zografi, G., "Interfacial Phenomena" in: <i>Remington's Pharmaceutical Sciences, Fifteenth Edition</i> , John E. Hoover, Editor, pp 285-298, Mack Publishing Co., Easton (1975).
440	Zotz et al., "The influence of Alunex on the pulmonary circulation in patients with pulmonary hypertension or left heart failure", <i>Eur. Heart Journal</i> 17(2):302-307 (1996).
	First Amended Complaint Alliance Pharmaceutical Corporation v. Nycomed AS et al., Civil Action No. 98CV 171 2E LAB (S.D. Cal. November 6, 1998).
	Complaint Alliance Pharmaceutical Corporation v. Nycomed AS et al., Civil Action No. 98CV 171 2E LAB (S.D. Cal. September 21, 1998).

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.